We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Aviva Plc (AV.) Ordinary Shares 32 17/19 pence

Sell:558.80p Buy:559.20p 0 Change: 1.60p (0.29%)
FTSE 100:0.08%
Market closed Prices as at close on 28 March 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Bid situation
Sell:558.80p
Buy:559.20p
Change: 1.60p (0.29%)
Market closed Prices as at close on 28 March 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Bid situation
Sell:558.80p
Buy:559.20p
Change: 1.60p (0.29%)
Market closed Prices as at close on 28 March 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Bid situation
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

HL comment (27 February 2025)

No recommendation - No news or research item is a personal recommendation to deal. All investments can fall as well as rise in value so you could get back less than you invest.

Aviva’s full-year General Insurance gross written premiums (GWP) increased 14%, excluding exchange rate effects, to £12.2bn. Operating profit rose 20% to £1.8bn (£1.7bn expected).

Growth was driven by strong performances in the UK & Ireland and Canada, with solid pricing, new business growth, and the Probitas acquisition boosting results. Protection sales surged 42%, driven by the AIG UK acquisition and double-digit Health growth. Retirement sales climbed 33%, supported by a record £7.8bn in Bulk Purchase Annuity transactions.

The Solvency II ratio, which measures capital strength against requirements, slipped to 203% from 207%.

The board announced a final dividend of 23.8p, lifting the total dividend by 7% to 35.7p.

The group is targeting operating profit of £2bn by 2026, with the dividend policy set for mid-single-digit growth.

The shares rose 2.3% in early trading.

Our view

Aviva’s ticking along nicely, with growth in 2024 coming across all its key markets and some well targeted acquisitions helping reduce the reliance on capital intensive business.

Aviva brings insurance, wealth, and retirement under one roof and the planned acquisition of Direct Line will bolster its market-leading positions in key areas like UK motor and home insurance. The deal terms require a decent chunk of cash so Aviva will tap its strong capital levels, and it’ll mean no buybacks for 2025, but we think the deal looks a good long-term move.

General insurance in the UK & Ireland saw more challenging conditions for parts of last year, but we’ve seen a sustained improvement over 2024. Higher prices are continuing to benefit key areas like motor and home insurance. It takes some time for these price hikes to feed through, but the benefits are starting to be felt. There’s still some work to be done in the Canadian business, but management is confident it’ll follow suit as we move into 2025.

Aviva's bulk annuity business (BPA), where it takes on final salary commitments from pension funds, has grown rapidly. The focus continues to be on finding the right new business rather than pushing for market share. These contracts feed significant quantities of new assets into the business, which Aviva Investors can manage - increasing scale and profitability.

Being a huge workplace pension provider is the logic behind increasing its presence in the wealth management market. Plans are also underway to expand the advisory offering which will help increase exposure to capital light businesses. Performance this year has been impressive, but it’s a tough market, so it's one to watch.

The retirement products sit alongside Aviva’s protection business (this includes products such as life assurance and income protection policies). And this year’s acquisition of AIG Life UK saw protection sales soar. This also houses the Health business which has been a benefactor of increased demand for private health insurance – a trend we see continuing.

Aviva is a diversified player with fingers in basically all the pies. The insurance business is starting to benefit from an improving market, momentum in the wealth management division continues to be impressive, and Aviva’s capitalising on the resurgence of activity in the bulk annuity market.

We like the mix, and with a strong balance sheet, the 7.2% prospective forward yield looks attractive. However, there are no guarantees, and there’s more pressure to deliver than there’s been for some time, increasing the risk of ups and downs.

Environmental, social and governance (ESG) risk

The financials sector is medium-risk in terms of ESG. Product governance is the largest risk for most companies, especially those in the US and Europe with enhanced regulatory scrutiny. Data privacy and security are also an increasingly important risk for banks and diversified financial firms. Business ethics, ESG integration and labour relations are also worth monitoring.

According to Sustainalytics, Aviva’s overall management of material ESG issues is strong.

Aviva values ESG management and focuses on transparency around key issues. The company actively addresses physical climate risks, data privacy, security, and sustainable finance. Aviva aims to boost sustainable investments by 2025 and integrates ESG factors into its investment strategies. The absence of customer satisfaction targets in FY2022 is a potential area for improvement.

An independent Non-Executive director of Hargreaves Lansdown plc is also an Independent Non-Executive Director of Aviva plc.

Aviva key facts

  • Forward price/earnings ratio (next 12 months): 10.3

  • Ten year average forward price/earnings ratio: 6.8

  • Prospective dividend yield (next 12 months): 7.2%

  • Ten year average prospective dividend yield: 8.6%

All ratios are sourced from LSEG Datastream, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.

This article is original Hargreaves Lansdown content, published by Hargreaves Lansdown. It was correct as at the date of publication, and our views may have changed since then. Unless otherwise stated estimates, including prospective yields, are a consensus of analyst forecasts provided by Refinitiv. These estimates are not a reliable indicator of future performance. Yields are variable and not guaranteed. Investments rise and fall in value so investors could make a loss.

This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.


Previous Aviva Plc updates

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.